Filter News

ADVENTRX Pharmaceuticals Inc. To Present CoFactor Phase II Results At American Society of Clinical Oncology Annual Conference

Published: May 30, 2006

SAN DIEGO, May 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. announced today that it will present updated results including median survival from its Phase II multi-center CoFactor(R) clinical trial at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting. The conference takes place June 2-6, 2006 in Atlanta, Georgia. The abstract entitled "5,10-methylenetetrahydrofolic acid with 5-fluorouracil as first line treatment in metastatic colorectal cancer: phase II study results" will be presented on Saturday, June 3 by Tony Reid, MD, Ph.D., the principal investigator for the clinical trial.

About CoFactor

CoFactor (ANX-510) is a folate-based biomodulator drug designed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-fluorouracil (5-FU). CoFactor creates more stable binding of the active form of 5-FU to the target enzyme, thymidylate synthase (TS), improving 5-FU performance. The Company reported Phase II results from an independent radiological assessment that found an overall clinical benefit of 85% and objective response of 35% in first line treatment of metastatic colorectal cancer with CoFactor and 5-FU. The Company also reported median time to tumor progression (TTP) of 163 days, with no study drug-related grade 3 or grade 4 gastrointestinal or hematological toxicity. The Company has received clearance under a special protocol assessment (SPA) from the US Food and Drug Administration (FDA) to begin a CoFactor Phase III pivotal clinical trial for metastatic colorectal cancer, which is currently planned to begin patient dosing in Q2 2006.

About ADVENTRX

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing treatments for cancer and infectious diseases that surpass the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. More information can be found on the Company's Web site at www.adventrx.com.

Forward Looking Statement

This press release contains forward-looking statements, within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, regarding ADVENTRX. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements regarding ADVENTRX, see the section titled "Risk Factors" in ADVENTRX's last annual report on Form 10-K and its Quarterly Reports on Form 10-Q, as well as other reports that ADVENTRX files from time to time with the Securities and Exchange Commission. All forward-looking statements regarding ADVENTRX are qualified in their entirety by this cautionary statement. ADVENTRX undertakes no obligation to release publicly any revisions to forward-looking statements to reflect events or circumstances which occur after the date hereof.

ADVENTRX Pharmaceuticals, Inc.

CONTACT: Andrea Lynn of ADVENTRX Pharmaceuticals, +1-858-552-0866/ /CNOCURL: http://www.prnewswire.com/gh/cnoc/comp/920134.html

Back to news